Tourmaline Bio

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Analysts

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ADUR

IBRX

TRML

This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

BBNX

CMPX

This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Penny Stocks

Small Cap

Intraday Update

Movers

ABTS

ALAB

AMTX

APYX

ARGX

ASST

AVGR

BPTS

CRML

CURI

CZOO

DRCT

FIVE

GOEV

HOUS

INTJ

JOAN

KAVL

LVWR

LXEH

MVLA

NSYS

OCGN

OTRK

PALT

PGEN

PRTG

PYXS

SPIR

STEM

TITN

WLDS

YTEN

Shares of  FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Tourmaline Bio Inc

TOURMALINE OIL CORP by Tourmaline Oil Corp.

Tourmaline Oil Corp

Management

Press Releases

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

Tourmaline Bio to Present at Upcoming Investor Conferences

Earnings

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Absci

Akebia Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Altimmune

Astria Therapeutics

Aura Biosciences

Candel Therapeutics

Celcuity

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Emergent BioSolutions

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Heron Therapeutics

Humacyte

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oruka Therapeutics

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Verastem

Wedbush

LifeSci Capital

Cantor Fitzgerald

HC Wainwright & Co.

BMO Capital

Comments

Tourmaline Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga